{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:56:11Z","timestamp":1790052971306,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006389","name":"University of Geneva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>As dual-phase amyloid-PET can evaluate amyloid (A) and neurodegeneration (N) with a single tracer injection, dual-phase tau-PET might be able to provide both tau (T) and N. Our study aims to assess the association of early-phase tau-PET scans and <jats:sup>18<\/jats:sup>F-fluorodeoxyglucose (FDG) PET and their comparability in discriminating Alzheimer\u2019s disease (AD) patients and differentiating neurodegenerative patterns.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>58 subjects evaluated at the Geneva Memory Center underwent dual-phase <jats:sup>18<\/jats:sup>F-Flortaucipir-PET with early-phase acquisition (eTAU) and <jats:sup>18<\/jats:sup>F-FDG-PET within 1 year. A subsample of 36 participants also underwent dual-phase amyloid-PET (eAMY). Standardized uptake value ratios (SUVRs) were calculated to assess the correlation of eTAU and their respective <jats:sup>18<\/jats:sup>F-FDG-PET and eAMY scans. Hypometabolism and hypoperfusion maps and their spatial overlap were also evaluated at the individual level visually and semiquantitatively. Receiver operating characteristic analyses were performed to compare the discriminative power of eTAU, FDG, and eAMY SUVR between A-\/T- and A+\/T\u2009+\u2009participants.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Strong positive correlations were found between eTAU and FDG SUVRs (<jats:italic>r<\/jats:italic>\u2009=\u20090.84, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and eTAU and eAMY SUVRs (<jats:italic>r<\/jats:italic>\u2009&gt;\u20090.87, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Clusters of significant hypoperfusion with good correspondence to hypometabolism topographies were found at the individual level, independently of the underlying neurodegenerative patterns. Both eTAU and FDG SUVRs significantly distinguished A+\/T\u2009+\u2009from A-\/T- individuals (AUC<jats:sub>eTAU<\/jats:sub>=0.604, AUC<jats:sub>FDG<\/jats:sub>=0.748) with FDG performing better than eTAU (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). eAMY and eTAU SUVR showed comparable discriminative power.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Early-phase <jats:sup>18<\/jats:sup>F-Flortaucipir-PET can provide perfusion information closely related to brain regional glucose metabolism and perfusion measured by early-phase amyloid-PET, even if less accurate than FDG-PET as a biomarker for neurodegeneration.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-024-07063-4","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T03:10:59Z","timestamp":1737688259000},"page":"1958-1969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Early-phase 18F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer\u2019s disease: a comparison with 18F-FDG-PET and early-phase amyloid-PET"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-436X","authenticated-orcid":false,"given":"Cecilia","family":"Boccalini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3033-8817","authenticated-orcid":false,"given":"Debora Elisa","family":"Peretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Mathoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ribaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Perani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2422-698X","authenticated-orcid":false,"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"7063_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14:535\u201362.","journal-title":"Alzheimer\u2019s Dement"},{"key":"7063_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1148\/radiol.2020200028","volume":"298","author":"VL Villemagne","year":"2021","unstructured":"Villemagne VL, Barkhof F, Garibotto V, Landau SM, Nordberg A, van Berckel BNM. Molecular imaging approaches in dementia. Radiology. 2021;298:517\u201330.","journal-title":"Radiology"},{"key":"7063_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","volume":"9","author":"R Ossenkoppele","year":"2013","unstructured":"Ossenkoppele R, Prins ND, Pijnenburg YAL, Lemstra AW, Van Der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer\u2019s Dement. 2013;9:414\u201321.","journal-title":"Alzheimer\u2019s Dement"},{"key":"7063_CR4","doi-asserted-by":"publisher","unstructured":"Garibotto V, Morbelli S, Pagani M. Dual-phase amyloid PET: hitting two birds with one stone. Eur J Nucl Med Mol Imaging [Internet]. 2016;43:1300\u20133. Available from: https:\/\/doi.org\/10.1007\/s00259-016-3393-6","DOI":"10.1007\/s00259-016-3393-6"},{"key":"7063_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2013.00070","volume":"5","author":"A Gjedde","year":"2013","unstructured":"Gjedde A, Aanerud J, Braendgaard H, Rodell AB. Blood-brain transfer of Pittsburgh compound B in humans. Front Aging Neurosci. 2013;5:1\u20139.","journal-title":"Front Aging Neurosci"},{"key":"7063_CR6","doi-asserted-by":"crossref","unstructured":"Jueptner M, Weiller C. Does measurement of regional cerebral blood flow reflect synaptic activity?\u2014Implications for PET and fMRI. NeuroImage. 1995. pp. 148\u201356.","DOI":"10.1006\/nimg.1995.1017"},{"key":"7063_CR7","doi-asserted-by":"publisher","unstructured":"Tiepolt S, Hesse S, Patt M, Luthardt J, Schroeter ML, Hoffmann KT et al. Early [18F]florbetaben and [11\u00a0C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging [Internet]. 2016;43:1700\u20139. Available from: https:\/\/doi.org\/10.1007\/s00259-016-3353-1","DOI":"10.1007\/s00259-016-3353-1"},{"key":"7063_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/s21155182","volume":"21","author":"AP Seiffert","year":"2021","unstructured":"Seiffert AP, G\u00f3mez-Grande A, Villarejo-Galende A, Gonz\u00e1lez-S\u00e1nchez M, Bueno H, G\u00f3mez EJ, et al. High correlation of static first-minute-frame (fmf) pet imaging after18f-labeled amyloid tracer injection with [18f]fdg pet imaging. Sensors. 2021;21:1\u201314.","journal-title":"Sensors"},{"key":"7063_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00259-011-2051-2","volume":"39","author":"IT Hsiao","year":"2012","unstructured":"Hsiao IT, Huang CC, Hsieh CJ, Hsu WC, Wey SP, Yen TC, et al. Correlation of early-phase 18F-florbetapir (AV-45\/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39:613\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7063_CR10","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2967\/jnumed.115.168732","volume":"57","author":"E Rodriguez-Vieitez","year":"2016","unstructured":"Rodriguez-Vieitez E, Carter SF, Chiotis K, Saint-Aubert L, Leuzy A, Sch\u00f6ll M, et al. Comparison of early-phase 11\u00a0C-Deuterium-L-Deprenyl and 11\u00a0C-Pittsburgh compound B PET for assessing Brain Perfusion in Alzheimer Disease. J Nucl Med. 2016;57:1071\u20137.","journal-title":"J Nucl Med"},{"key":"7063_CR11","doi-asserted-by":"crossref","unstructured":"Boccalini C, Peretti DE, Ribaldi F, Scheffler M, Stampacchia S, Tomczyk S et al. Early-phase 18 F-Florbetapir and 18 F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting. J Nucl Med. 2022;jnumed.122.264256.","DOI":"10.2967\/jnumed.122.264256"},{"key":"7063_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2967\/jnumed.110.083683","volume":"52","author":"PT Meyer","year":"2011","unstructured":"Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and11C-Labeled Pittsburgh compound B. J Nucl Med. 2011;52:393\u2013400.","journal-title":"J Nucl Med"},{"key":"7063_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2967\/jnumed.110.082057","volume":"52","author":"AH Rostomian","year":"2011","unstructured":"Rostomian AH, Madison C, Rabinovici GD, Jagust WJ. Early 11\u00a0C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med. 2011;52:173\u20139.","journal-title":"J Nucl Med"},{"key":"7063_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1177\/0271678X16645593","volume":"37","author":"E Rodriguez-Vieitez","year":"2017","unstructured":"Rodriguez-Vieitez E, Leuzy A, Chiotis K, Saint-Aubert L, Wall A, Nordberg A. Comparability of [18F]THK5317 and [11\u00a0C]PIB blood flow proxy images with [18F]FDG Positron emission tomography in Alzheimer\u2019s disease. J Cereb Blood Flow Metab. 2017;37:740\u20139.","journal-title":"J Cereb Blood Flow Metab"},{"key":"7063_CR15","doi-asserted-by":"publisher","unstructured":"Daerr S, Brendel M, Zach C, Mille E, Schilling D, Zacherl MJ et al. Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases. NeuroImage Clin [Internet]. 2017;14:77\u201386. Available from: https:\/\/doi.org\/10.1016\/j.nicl.2016.10.005","DOI":"10.1016\/j.nicl.2016.10.005"},{"key":"7063_CR16","doi-asserted-by":"publisher","unstructured":"Ottoy J, Verhaeghe J, Niemantsverdriet E, De Roeck E, wyffels L, Ceyssens S et al. 18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer\u2019s disease: Validation against 15O-H2O PET. Alzheimer\u2019s Dement [Internet]. 2019;15:1172\u201382. Available from: https:\/\/doi.org\/10.1016\/j.jalz.2019.05.010","DOI":"10.1016\/j.jalz.2019.05.010"},{"key":"7063_CR17","first-page":"1","volume":"14","author":"DE Peretti","year":"2019","unstructured":"Peretti DE, Garc\u00eda DV, Reesink FE, Van der Goot T, De Deyn PP, De Jong BM, et al. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer\u2019s disease PET studies. PLoS ONE. 2019;14:1\u201319.","journal-title":"PLoS ONE"},{"key":"7063_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nicl.2021.102750","volume":"31","author":"M Vanhoutte","year":"2021","unstructured":"Vanhoutte M, Landeau B, Sherif S, de la Sayette V, Dautricourt S, Abbas A, et al. Evaluation of the early-phase [18F]AV45 PET as an optimal surrogate of [18F]FDG PET in ageing and Alzheimer\u2019s clinical syndrome. NeuroImage Clin. 2021;31:1\u201315.","journal-title":"NeuroImage Clin"},{"key":"7063_CR19","doi-asserted-by":"publisher","unstructured":"Forsberg A, Engler H, Blomquist G, L\u00e5ngstr\u00f6m B, Nordberg A. The use of PIB-PET as a dual pathological and functional biomarker in AD. Biochim Biophys Acta - Mol Basis Dis [Internet]. 2012;1822:380\u20135. Available from: https:\/\/doi.org\/10.1016\/j.bbadis.2011.11.006","DOI":"10.1016\/j.bbadis.2011.11.006"},{"key":"7063_CR20","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1007\/s00259-020-04788-w","volume":"47","author":"L Beyer","year":"2020","unstructured":"Beyer L, Nitschmann A, Barthel H, van Eimeren T, Unterrainer M, Sauerbeck J, et al. Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. Eur J Nucl Med Mol Imaging. 2020;47:2911\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7063_CR21","doi-asserted-by":"publisher","unstructured":"V\u00f6lter F, Beyer L, Eckenweber F, Scheifele M, Bui N, Patt M et al. Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings. Eur J Nucl Med Mol Imaging [Internet]. 2022; Available from: https:\/\/doi.org\/10.1007\/s00259-022-06087-y","DOI":"10.1007\/s00259-022-06087-y"},{"key":"7063_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:270\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"key":"7063_CR23","doi-asserted-by":"publisher","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement [Internet]. 2011;7:263\u20139. Available from: https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"7063_CR24","doi-asserted-by":"crossref","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004\/08\/25. 2004;256:183\u201394.","DOI":"10.1111\/j.1365-2796.2004.01388.x"},{"key":"7063_CR25","unstructured":"Schmidt P. Bayesian inference for structured additive regression models for large-scale problems with applications to medical imaging. Dissertation, LMU M\u00fcnchen: Faculty of Mathematics, Computer Science and Statistics. 2016;Chap. 6.1. Available from: https:\/\/edoc.ub.uni-muenchen.de\/20373\/"},{"key":"7063_CR26","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1161\/01.STR.32.6.1318","volume":"32","author":"LO Wahlund","year":"2001","unstructured":"Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sj\u00f6gren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318\u201322.","journal-title":"Stroke"},{"key":"7063_CR27","doi-asserted-by":"publisher","unstructured":"Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B et al. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging [Internet]. 2021; Available from: https:\/\/doi.org\/10.1007\/s00259-021-05603-w","DOI":"10.1007\/s00259-021-05603-w"},{"key":"7063_CR28","doi-asserted-by":"crossref","unstructured":"Schmitt J, Palleis C, Sauerbeck J, Unterrainer M, Harris S, Prix C et al. Dual-phase \u03b2-Amyloid PET captures neuronal Injury and Amyloidosis in Corticobasal Syndrome. Front Aging Neurosci. 2021;13.","DOI":"10.3389\/fnagi.2021.661284"},{"key":"7063_CR29","doi-asserted-by":"publisher","unstructured":"Rolls ET, Huang CC, Lin CP, Feng J, Joliot M. Automated anatomical labelling atlas 3. Neuroimage [Internet]. 2020;206:116189. Available from: https:\/\/doi.org\/10.1016\/j.neuroimage.2019.116189","DOI":"10.1016\/j.neuroimage.2019.116189"},{"key":"7063_CR30","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","volume":"32","author":"SM Landau","year":"2011","unstructured":"Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207\u201318.","journal-title":"Neurobiol Aging"},{"key":"7063_CR31","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1002\/mds.23291","volume":"25","author":"LK Teune","year":"2010","unstructured":"Teune LK, Bartels AL, De Jong BM, Willemsen ATM, Eshuis SA, De Vries JJ, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010;25:2395\u2013404.","journal-title":"Mov Disord"},{"key":"7063_CR32","doi-asserted-by":"crossref","unstructured":"Jeong SH, Cha J, Yoo HS, Chung SJ, Jung JH, Sohn YH et al. Different effect of hypo- and hypermetabolism on cognition in dementia with Lewy bodies: are they coupled or independent? Npj Park Dis. 2024;10.","DOI":"10.1038\/s41531-023-00622-w"},{"key":"7063_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.nicl.2014.10.009","volume":"6","author":"D Perani","year":"2014","unstructured":"Perani D, Della Rosa PA, Cerami C, Gallivanone F, Fallanca F, Vanoli EG, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage Clin. 2014;6:445\u201354.","journal-title":"NeuroImage Clin"},{"key":"7063_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12021-016-9322-9","volume":"15","author":"L Presotto","year":"2017","unstructured":"Presotto L, Ballarini T, Caminiti SP, Bettinardi V, Gianolli L, Perani D. Validation of 18F\u2013FDG-PET single-subject optimized SPM Procedure with different PET scanners. Neuroinformatics. 2017;15:151\u201363.","journal-title":"Neuroinformatics"},{"key":"7063_CR35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12021-014-9235-4","volume":"12","author":"PA Della Rosa","year":"2014","unstructured":"Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical Parametric Mapping of Dementia. Neuroinformatics. 2014;12:575\u201393.","journal-title":"Neuroinformatics"},{"key":"7063_CR36","unstructured":"Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. FSL 1. Neuroimage. 2012."},{"key":"7063_CR37","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.2967\/jnumed.116.185835","volume":"58","author":"A Savio","year":"2017","unstructured":"Savio A, F\u00fcnger S, Tahmasian M, Rachakonda S, Manoliu A, Sorg C, et al. Resting-state networks as simultaneously measured with functional MRI and PET. J Nucl Med. 2017;58:1314\u20137.","journal-title":"J Nucl Med"},{"key":"7063_CR38","doi-asserted-by":"crossref","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;837\u201345.","DOI":"10.2307\/2531595"},{"key":"7063_CR39","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/BF00181059","volume":"21","author":"R Mielke","year":"1994","unstructured":"Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, et al. HMPAO SPET and FDG PET in Alzheimer\u2019s disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med. 1994;21:1052\u201360.","journal-title":"Eur J Nucl Med"},{"key":"7063_CR40","doi-asserted-by":"crossref","unstructured":"Dilcher R, Wagemann O, Wall S, Palleis C, Gro\u00df M, Katzdobler S et al. Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer \u2019 s disease and 4R-tauopathies. 2024;6896\u2013909.","DOI":"10.1002\/alz.14185"},{"key":"7063_CR41","doi-asserted-by":"publisher","unstructured":"Tuncel H, Visser D, Timmers T, Wolters EE, Ossenkoppele R, van der Flier WM et al. Head-to-head comparison of relative cerebral blood flow derived from dynamic [18F]florbetapir and [18F]flortaucipir PET in subjects with subjective cognitive decline. EJNMMI Res [Internet]. 2023;13. Available from: https:\/\/doi.org\/10.1186\/s13550-023-01041-x","DOI":"10.1186\/s13550-023-01041-x"},{"key":"7063_CR42","doi-asserted-by":"crossref","unstructured":"Boccalini C, Ribaldi F, Hristovska I, Arnone A, Peretti D, Mu L, et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Accept Publ Alzheimer\u2019s Dement; 2023.","DOI":"10.1002\/alz.13355"},{"key":"7063_CR43","first-page":"594","volume":"45","author":"DHS Silverman","year":"2004","unstructured":"Silverman DHS. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004;45:594\u2013607.","journal-title":"J Nucl Med"},{"key":"7063_CR44","doi-asserted-by":"publisher","unstructured":"Visser D, Verfaillie SCJ, Wolters EE, Coomans EM, Timmers T, Tuncel H et al. Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging [Internet]. 2022;49:1951\u201363. Available from: https:\/\/doi.org\/10.1007\/s00259-021-05669-6","DOI":"10.1007\/s00259-021-05669-6"},{"key":"7063_CR45","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s11307-021-01581-5","volume":"23","author":"H Tuncel","year":"2021","unstructured":"Tuncel H, Visser D, Yaqub M, Timmers T, Wolters EE, Ossenkoppele R, et al. Effect of shortening the scan duration on quantitative accuracy of [18F]Flortaucipir studies. Mol Imaging Biol. 2021;23:604\u201313.","journal-title":"Mol Imaging Biol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-07063-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-07063-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-07063-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:26:31Z","timestamp":1745317591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-07063-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["7063"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-07063-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VG received research support and speaker fees through her institution from GE Healthcare, Siemens Healthineers, Janssen and Novo Nordisk. LI is a full-time employee of Eli Lilly and company. GBF has received support, payment, consulting fees, or honoraria through his institution for lectures, presentations, speaker bureaus, manuscript writing, or educations events from: Biogen, Roche, Diadem, Novo Nordisk, GE Healthcare, OM Pharma, and Eisai.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and the subjects\u2019 consent has been waived from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to participate"}},{"value":"The study\u2019s protocol has been approved by our local Geneva Ethics Committee (NO 2016\u201301346).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}